The utility of feNO in the differential diagnosis of chronic cough: The response to anti-inflammatory therapy with prednisolone and montelukast - The utility of feNO in the differential diagnosis of chronic cough

Hull and East Yorkshire Hospitals NHS trust0 sites50 target enrollmentSeptember 18, 2015

Overview

No summary available.

Registry

who.int

Start Date

September 18, 2015

End Date

March 9, 2017

Last Updated

6 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

Hull and East Yorkshire Hospitals NHS trust

•Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.
•Patients with a history of chronic cough (at least 8 weeks duration)
•Male and female subjects of at least 18 yrs of age
•Subjects able to understand the study and co\-operate with the study procedures
•Subjects who consent to their general practitioner (GP) being informed of their study participation.
•Patients with a FeNO\=30ppb at presentation to the Chronic cough clinic.( required for entry on to the high FeNO treatment groups)
•Patients with FeNO\=20 ppb at presentation to the chronic cough clinic (required for entry as a normal FeNO treatment group)
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1\.2 Adults (18\-64 years) yes

•Patients with current diagnosis of asthma.
•Female subjects who are pregnant, or lactating, or who are of child bearing potential but are not using contraceptive measures
•Suffering from any concomitant disease (chronic heart, chronic lung such as; COPD, bronchiectasis and cystic fibrosis, chronic renal, chronic liver or neuromuscular disease or immunosuppression; pneumonia and diabetes) which may interfere with study procedures or evaluation.
•A lower respiratory tract infection 4 weeks prior to entry on to study
•Systemic infections
•Live virus immunisation planned within next 3 months
•Subjects with no previous chickenpox who had a recent (\<\=28 days) close personal contact with chickenpox OR herpes zoster (high FeNO treatment groups only)
•Subjects having recent (\<\=28 days) exposure to measles (high FeNO treatment groups only)
•Participation in another study (use of investigational product) within 30 days preceding entry on to study.
•Alcohol or drug abuse